Q32 Bio downgraded to Outperform from Strong Buy at Raymond James

Raymond James analyst Steven Seedhouse downgraded Q32 Bio (QTTB) to Outperform from Strong Buy with a price target of $22, down from $90, following the Phase 2 data update for bempikibart. The firm says it underestimated the negative market reaction in “this mixed data scenario” but still believes the company’s IL7R-4 mechanism “is not a zero.”

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue